{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T23:39:11Z","timestamp":1769125151152,"version":"3.49.0"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.phrs.2022.106629","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T12:04:06Z","timestamp":1671710646000},"page":"106629","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Lipodystrophies in non-insulin-dependent children: Treatment options and results from recombinant human leptin therapy"],"prefix":"10.1016","volume":"187","author":[{"given":"Valeria","family":"Calcaterra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittoria Carlotta","family":"Magenes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Fabiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Mameli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianvincenzo","family":"Zuccotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2022.106629_bib1","series-title":"Endotext","article-title":"Lipodystrophy syndromes: presentation and treatment","author":"Akinci","year":"2000"},{"key":"10.1016\/j.phrs.2022.106629_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4274\/jcrpe.galenos.2019.2019.0124","article-title":"Current diagnosis, treatment and clinical challenges in the management of lipodystrophy syndromes in children and young people","volume":"12","author":"\u00d6zen","year":"2020","journal-title":"Jcrpe"},{"key":"10.1016\/j.phrs.2022.106629_bib3","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1677\/JOE-10-0272","article-title":"Lipodystrophy: metabolic insights from a rare disorder","volume":"207","author":"Huang-Doran","year":"2010","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.phrs.2022.106629_bib5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2147\/DMSO.S130810","article-title":"Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges","volume":"10","author":"Chiquette","year":"2017","journal-title":"DMSO"},{"key":"10.1016\/j.phrs.2022.106629_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2337\/db19-0447","article-title":"Clinical and molecular prevalence of lipodystrophy in an unascertained large clinical care cohort","volume":"69","author":"Gonzaga-Jauregui","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2022.106629_bib7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1210\/jc.2016-2271","article-title":"Clinical features and management of non-HIV\u2013related lipodystrophy in children: a systematic review","volume":"102","author":"Gupta","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4158\/endp.19.1.v767575m65p5mr06","article-title":"The clinical approach to the detection of lipodystrophy an aace consensus statement","volume":"19","author":"Handelsman","year":"2013","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.phrs.2022.106629_bib9","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jc.2011-1159","article-title":"Lipodystrophies: genetic and acquired body fat disorders","volume":"96","author":"Garg","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib10","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ecl.2017.01.012","article-title":"Genetics of lipodystrophy","volume":"46","author":"Lightbourne","year":"2017","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"10.1016\/j.phrs.2022.106629_bib11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13104-015-1065-4","article-title":"Familial partial lipodystrophy, dunnigan variety - challenges for patient care during pregnancy: a case report","volume":"8","author":"Belo","year":"2015","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.phrs.2022.106629_bib12","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/cen.13311","article-title":"Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort","volume":"86","author":"Ajluni","year":"2017","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.phrs.2022.106629_bib13","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.3390\/diagnostics12051122","article-title":"Familial partial lipodystrophy\u2014literature review and report of a novel variant in PPARG expanding the spectrum of disease-causing alterations in FPLD3","volume":"12","author":"Rutkowska","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.phrs.2022.106629_bib14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00005792-200303000-00007","article-title":"Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature","volume":"82","author":"Misra","year":"2003","journal-title":"Medicine"},{"key":"10.1016\/j.phrs.2022.106629_bib15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.md.0000111061.69212.59","article-title":"Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature","volume":"83","author":"Misra","year":"2004","journal-title":"Medicine"},{"key":"10.1016\/j.phrs.2022.106629_bib16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ecl.2004.03.003","article-title":"Lipodystrophies: rare disorders causing metabolic syndrome","volume":"33","author":"Garg","year":"2004","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"10.1016\/j.phrs.2022.106629_bib17","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJMra025261","article-title":"Acquired and inherited lipodystrophies","volume":"350","author":"Garg","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2022.106629_bib18","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1525-1470.2010.01255.x","article-title":"Acquired partial lipodystrophy with C3 hypocomplementemia and antiphospholipid and anticardiolipin antibodies: antiphospholipid and anticardiolipin antibodies in APL","volume":"27","author":"Yavuz","year":"2010","journal-title":"Pediatr. Dermatol."},{"key":"10.1016\/j.phrs.2022.106629_bib19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11892-018-1099-9","article-title":"Phenotypic and genetic characteristics of lipodystrophy: pathophysiology, metabolic abnormalities, and comorbidities","volume":"18","author":"Akinci","year":"2018","journal-title":"Curr. Diabetes Rep."},{"key":"10.1016\/j.phrs.2022.106629_bib20","doi-asserted-by":"crossref","first-page":"E192","DOI":"10.1210\/jc.2010-0419","article-title":"A novel syndrome of mandibular hypoplasia, deafness, and progeroid features associated with lipodystrophy, undescended testes, and male hypogonadism","volume":"95","author":"Shastry","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib21","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00431-015-2668-4","article-title":"CANDLE syndrome: chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature\u2014a rare case with a novel mutation","volume":"175","author":"Cavalcante","year":"2016","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.phrs.2022.106629_bib22","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajhg.2013.05.023","article-title":"SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling","volume":"93","author":"Chudasama","year":"2013","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.phrs.2022.106629_bib23","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1002\/ajmg.a.34249","article-title":"N\u00e9stor-Guillermo Progeria syndrome: a novel premature aging condition with early onset and chronic development caused by BANF1 mutations","volume":"155","author":"Cabanillas","year":"2011","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.phrs.2022.106629_bib24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1750-1172-8-106","article-title":"Partial lipodystrophy with severe insulin resistance and adult Progeria Werner syndrome","volume":"8","author":"Donadille","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.phrs.2022.106629_bib25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1297\/cpe.22.53","article-title":"Abnormal adipose tissue distribution with unfavorable metabolic profile in five children following hematopoietic stem cell transplantation: a new etiology for acquired partial lipodystrophy","volume":"22","author":"Adachi","year":"2013","journal-title":"Clin. Pediatr. Endocrinol."},{"key":"10.1016\/j.phrs.2022.106629_bib26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1297\/cpe.26.99","article-title":"Partial lipodystrophy in patients who have undergone hematopoietic stem cell transplantation during childhood: an institutional cross-sectional survey","volume":"26","author":"Adachi","year":"2017","journal-title":"Clin. Pediatr. Endocrinol."},{"key":"10.1016\/j.phrs.2022.106629_bib27","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s40618-017-0731-x","article-title":"Acquired partial lipodystrophy after bone marrow transplant during childhood: a novel syndrome to be added to the disease classification list","volume":"40","author":"Ceccarini","year":"2017","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.phrs.2022.106629_bib28","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3390\/jcm10081559","article-title":"Lipodystrophy as a late effect after stem cell transplantation","volume":"10","author":"Tews","year":"2021","journal-title":"JCM"},{"key":"10.1016\/j.phrs.2022.106629_bib29","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1515\/jpem-2018-0356","article-title":"Acquired partial lipodystrophy with metabolic disease in children following hematopoietic stem cell transplantation: a report of two cases and a review of the literature","volume":"32","author":"Hosokawa","year":"2019","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib30","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1210\/jc.2015-2476","article-title":"A novel syndrome of generalized lipodystrophy associated with pilocytic astrocytoma","volume":"100","author":"Patni","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib31","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1210\/jc.2018-02221","article-title":"Acquired lipodystrophy associated with nivolumab in a patient with advanced renal cell carcinoma","volume":"104","author":"Falcao","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105131","article-title":"Lipid-mediated regulation of the cancer-immune crosstalk","volume":"161","author":"Ma","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2022.106629_bib33","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.diabet.2013.05.006","article-title":"Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes","volume":"39","author":"Blanco","year":"2013","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib34","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.dsx.2018.04.023","article-title":"Insulin related lipodystrophic lesions and hypoglycemia: double standards?","volume":"12","author":"Gentile","year":"2018","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"10.1016\/j.phrs.2022.106629_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(03)00246-6","article-title":"HIV-related lipodystrophy and related factors","volume":"174","author":"Tershakovec","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2022.106629_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/7013758","article-title":"The lipodystrophy syndrome in HIV-infected children under antiretroviral therapy: a first report from the Central Africa","volume":"2019","author":"Tshamala","year":"2019","journal-title":"Int. J. Pediatr."},{"key":"10.1016\/j.phrs.2022.106629_bib37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00431-006-0193-1","article-title":"Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study","volume":"166","author":"Ene","year":"2006","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.phrs.2022.106629_bib38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3945\/ajcn.2008.26733","article-title":"Association of prepubertal body composition in healthy girls and boys with the timing of early and late pubertal markers","volume":"89","author":"Buyken","year":"2009","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.phrs.2022.106629_bib39","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4314\/ahs.v14i2.17","article-title":"Lipodystrophy syndrome among HIV infected children on highly active antiretroviral therapy in Northern India","volume":"14","author":"Bhutia","year":"2014","journal-title":"Afr. Health Sci."},{"key":"10.1016\/j.phrs.2022.106629_bib40","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.bjid.2013.12.007","article-title":"Prevalence of lipodystrophy and risk factors for dyslipidemia in HIV-infected children in Brazil","volume":"18","author":"Papi","year":"2014","journal-title":"Braz. J. Infect. Dis."},{"key":"10.1016\/j.phrs.2022.106629_bib41","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2223\/JPED.1910","article-title":"Lipodystrophy in children and adolescents with acquired immunodeficiency syndrome and its relationship with the antiretroviral therapy employed","volume":"85","author":"Sarni","year":"2009","journal-title":"J. Pediatr."},{"key":"10.1016\/j.phrs.2022.106629_bib42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40618-018-0887-z","article-title":"Diagnosis and treatment of lipodystrophy: a step-by-step approach","volume":"42","author":"Ara\u00fajo-Vilar","year":"2019","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.phrs.2022.106629_bib43","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11892-018-1100-7","article-title":"Update on therapeutic options in lipodystrophy","volume":"18","author":"Akinci","year":"2018","journal-title":"Curr. Diabetes Rep."},{"key":"10.1016\/j.phrs.2022.106629_bib44","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4158\/EP09154.RA","article-title":"Clinical classification and treatment of congenital and acquired lipodystrophy","volume":"16","author":"Chan","year":"2010","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.phrs.2022.106629_bib45","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1172\/JCI129190","article-title":"What lipodystrophies teach us about the metabolic syndrome","volume":"129","author":"Mann","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.phrs.2022.106629_bib46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.metabol.2017.04.010","article-title":"Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy","volume":"72","author":"Akinci","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.phrs.2022.106629_bib47","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1210\/jc.2003-030855","article-title":"Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy","volume":"88","author":"Agarwal","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib48","first-page":"59","article-title":"Phenotypic heterogeneity in patients with familial partial lipodystrophy (dunnigan variety) related to the site of missense mutations in lamin a\/c gene","volume":"86","author":"Garg","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib49","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00125-002-0873-y","article-title":"Adipose tissue as a buffer for daily lipid flux","volume":"45","author":"Frayn","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.phrs.2022.106629_bib50","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cmet.2016.04.011","article-title":"Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk","volume":"23","author":"Stern","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib51","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nature05488","article-title":"Abdominal obesity and metabolic syndrome","volume":"444","author":"Despr\u00e9s","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2022.106629_bib52","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.metabol.2014.08.004","article-title":"Physiology of leptin: energy homeostasis, neuroendocrine function and metabolism","volume":"64","author":"Park","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.phrs.2022.106629_bib53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cmet.2013.05.010","article-title":"Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives","volume":"18","author":"Dalamaga","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib54","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1210\/er.2012-1053","article-title":"Leptin\u2019s role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals","volume":"34","author":"Moon","year":"2013","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.phrs.2022.106629_bib55","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/jhg.2013.107","article-title":"Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies","volume":"59","author":"Nolis","year":"2014","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.phrs.2022.106629_bib56","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1210\/clinem\/dgac079","article-title":"Approach to the patient with lipodystrophy","volume":"107","author":"Fourman","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib57","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1515\/jpem-2017-0355","article-title":"Clinical outcome in a series of pediatric patients with congenital generalized lipodystrophies treated with dietary therapy","volume":"31","author":"Papendieck","year":"2018","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib58","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/17446651.2020.1735360","article-title":"Diagnostic strategies and clinical management of lipodystrophy","volume":"15","author":"Foss-Freitas","year":"2020","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib59","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1172\/JCI38660","article-title":"Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy","volume":"119","author":"Hayashi","year":"2009","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.phrs.2022.106629_bib60","doi-asserted-by":"crossref","first-page":"E1493","DOI":"10.1210\/jc.2014-1353","article-title":"Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy","volume":"99","author":"Christensen","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib61","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.1210\/jc.2002-020792","article-title":"Effect of subcutaneous leptin replacement therapy on bone metabolism in patients with generalized lipodystrophy","volume":"87","author":"Simha","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib62","doi-asserted-by":"crossref","first-page":"7054","DOI":"10.1073\/pnas.1324025111","article-title":"Lack of testicular seipin causes teratozoospermia syndrome in men","volume":"111","author":"Jiang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2022.106629_bib63","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2217\/clp.14.13","article-title":"Diagnosis and management of lipodystrophy: a practical update","volume":"9","author":"Stears","year":"2014","journal-title":"Clin. Lipidol."},{"key":"10.1016\/j.phrs.2022.106629_bib64","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4103\/2229-5178.137765","article-title":"An approach to Acanthosis Nigricans","volume":"5","author":"Phiske","year":"2014","journal-title":"Indian Dermatol. Online J."},{"key":"10.1016\/j.phrs.2022.106629_bib65","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MOL.0b013e32832d4a33","article-title":"Inherited lipodystrophies and hypertriglyceridemia","volume":"20","author":"Simha","year":"2009","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.phrs.2022.106629_bib66","doi-asserted-by":"crossref","first-page":"E1676","DOI":"10.1210\/jc.2014-1878","article-title":"Lipid regulation in lipodystrophy versus the obesity-associated metabolic syndrome: the dissociation of HDL-C and triglycerides","volume":"99","author":"Joseph","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib67","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.metabol.2019.05.001","article-title":"Fatty liver in lipodystrophy: a review with a focus on therapeutic perspectives of adiponectin and\/or leptin replacement","volume":"96","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.phrs.2022.106629_bib68","doi-asserted-by":"crossref","DOI":"10.1210\/js.2019-MON-104","article-title":"MON-104 defining the contribution of weight to the extent of metabolic disease in FPLD: insights from a retrospective \u201cmatched\u201d case-control study","volume":"3","author":"Koo","year":"2019","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.phrs.2022.106629_bib69","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ejmg.2016.05.001","article-title":"Spectrum of clinical manifestations in two young Turkish patients with congenital generalized lipodystrophy type 4","volume":"59","author":"Akinci","year":"2016","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.phrs.2022.106629_bib70","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.2337\/db17-1236","article-title":"A pharmacogenetic approach to the treatment of patients with PPARG mutations","volume":"67","author":"Agostini","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2022.106629_bib71","doi-asserted-by":"crossref","first-page":"656","DOI":"10.4158\/EP.13.6.656","article-title":"Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome","volume":"13","author":"Sleilati","year":"2007","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.phrs.2022.106629_bib72","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.metabol.2009.04.043","article-title":"Clinical characteristics and efficacy of pioglitazone in a Japanese diabetic patient with an unusual type of familial partial lipodystrophy","volume":"58","author":"Iwanishi","year":"2009","journal-title":"Metabolism"},{"key":"10.1016\/j.phrs.2022.106629_bib73","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.2337\/diacare.28.5.1240","article-title":"The use of U-500 in patients with extreme insulin resistance","volume":"28","author":"Cochran","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2022.106629_bib74","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13256-016-1175-1","article-title":"Glucagon-like peptide-1 analogues - an efficient therapeutic option for the severe insulin resistance of lipodystrophic syndromes: two case reports","volume":"11","author":"Oliveira","year":"2017","journal-title":"J. Med. Case Rep."},{"key":"10.1016\/j.phrs.2022.106629_bib75","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2337\/db16-0733","article-title":"The sodium\u2013glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model","volume":"66","author":"Joubert","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2022.106629_bib76","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1530\/EJE-12-0969","article-title":"Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trial","volume":"168","author":"Ahmad","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.phrs.2022.106629_bib77","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.2337\/dc12-1529","article-title":"Type 2 diabetes with partial lipodystrophy of the limbs","volume":"36","author":"Strickland","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2022.106629_bib78","unstructured":"Myalepta - Metreleptin (EMA Approval) Available online: \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/myalepta\u3009."},{"key":"10.1016\/j.phrs.2022.106629_bib79","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2022.106629_bib80","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/43448","article-title":"Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy","volume":"401","author":"Shimomura","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2022.106629_bib81","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.diabet.2016.08.004","article-title":"One-year metreleptin therapy decreases PCSK9 serum levels in diabetic patients with monogenic lipodystrophy syndromes","volume":"43","author":"Vatier","year":"2017","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib82","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s12020-018-1589-1","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy","volume":"60","author":"Brown","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.phrs.2022.106629_bib83","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s12020-014-0450-4","article-title":"Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience","volume":"49","author":"Araujo-Vilar","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.phrs.2022.106629_bib84","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/nbt0414-300b","article-title":"Leptin therapy gains FDA approval","volume":"32","author":"Sinha","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.phrs.2022.106629_bib85","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2014-4491","article-title":"Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin","volume":"100","author":"Diker-Cohen","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib86","first-page":"659","article-title":"Efficacy and safety of metreleptin in patients with partial lipodystrophy: lessons from an expanded access program","volume":"7","author":"Ajluni","year":"2016","journal-title":"J. Diabetes Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib87","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1210\/jc.2011-2229","article-title":"Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan Variety","volume":"97","author":"Simha","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib88","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2337\/db15-1550","article-title":"Leptin substitution in patients with lipodystrophy: neural correlates for long-term success in the normalization of eating behavior","volume":"65","author":"Schl\u00f6gl","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2022.106629_bib89","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.metabol.2003.10.019","article-title":"Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy","volume":"53","author":"Moran","year":"2004","journal-title":"Metabolism"},{"key":"10.1016\/j.phrs.2022.106629_bib90","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1172\/JCI91578","article-title":"The long road to leptin","volume":"126","author":"Friedman","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.phrs.2022.106629_bib91","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1172\/JCI95476","article-title":"Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy","volume":"128","author":"Brown","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.phrs.2022.106629_bib92","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI0215001","article-title":"Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy","volume":"109","author":"Petersen","year":"2002","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.phrs.2022.106629_bib93","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1210\/jc.2015-2589","article-title":"A report of three cases with acquired generalized lipodystrophy with distinct autoimmune conditions treated with metreleptin","volume":"100","author":"Lebastchi","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib94","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1210\/jc.2016-3628","article-title":"Effects of metreleptin in pediatric patients with lipodystrophy","volume":"102","author":"Brown","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib95","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1210\/jc.2003-032140","article-title":"Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy","volume":"89","author":"Javor","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib96","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1210\/jcem.87.7.8591","article-title":"Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy","volume":"87","author":"Oral","year":"2002","journal-title":"Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib97","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1159\/000439432","article-title":"Effects of recombinant human leptin (metreleptin) on nocturnal luteinizing hormone secretion in lipodystrophy patients","volume":"103","author":"Abel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.phrs.2022.106629_bib98","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1210\/jc.2011-1896","article-title":"Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovarian syndrome","volume":"97","author":"Lungu","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2022.106629_bib99","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/AOG.0b013e31822cecf7","article-title":"Pregnancy in a woman with congenital generalized lipodystrophy: leptin\u2019s vital role in reproduction","volume":"119","author":"Maguire","year":"2012","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.phrs.2022.106629_bib100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1586\/17512433.2016.1096772","article-title":"Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy","volume":"9","author":"Meehan","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2022.106629_bib101","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000341398","article-title":"Consequences of stopping and restarting leptin in an adolescent with lipodystrophy","volume":"78","author":"Kamran","year":"2012","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.phrs.2022.106629_bib102","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cen.12980","article-title":"Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy","volume":"85","author":"Chan","year":"2016","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.phrs.2022.106629_bib103","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1530\/EJE-09-1027","article-title":"Resistance to leptin-replacement therapy in Berardinelli-Seip congenital lipodystrophy: an immunological origin","volume":"162","author":"Beltrand","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.phrs.2022.106629_bib104","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/10428194.2015.1040015","article-title":"Lymphoma in acquired generalized lipodystrophy","volume":"57","author":"Brown","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.phrs.2022.106629_bib105","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/ijd.12185","article-title":"Acquired generalized lipodystrophy associated with peripheral T cell lymphoma with cutaneous infiltration","volume":"54","author":"Aslam","year":"2015","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.phrs.2022.106629_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.879979","article-title":"Treatment options for lipodystrophy in children","volume":"13","author":"Mainieri","year":"2022","journal-title":"Front. Endocrinol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822005758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822005758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:45:12Z","timestamp":1760913912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822005758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":106,"alternative-id":["S1043661822005758"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106629","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipodystrophies in non-insulin-dependent children: Treatment options and results from recombinant human leptin therapy","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106629","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106629"}}